Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 740 adults with hepatitis C — 371 in one group and 369 in the other. Both groups received a combination of three medicines: telaprevir (taken either every 8 hours or twice daily) together with two other hepatitis C drugs, peginterferon and ribavirin. The trial was primarily measuring what proportion of participants had undetectable levels of the hepatitis C virus in their blood 12 weeks after finishing their planned course of treatment — a result known as a "sustained virologic response" or SVR (meaning the virus was no longer measurable at that later check-up point). The reported data shows that for the primary measure — virus undetectable at 12 weeks after the planned end of treatment — 72.8% of participants in the every-8-hours group and 74.3% in the twice-daily group met that threshold. For a similar check at 24 weeks after planned treatment end, the figures were 72.8% and 74.8% respectively, and at 72 weeks from the start of treatment they were 69.0% and 70.2%. The reported data also shows that around 9.7% and 10.3% of participants in each group respectively had to stop all study drugs early because the virus remained detectable at levels that triggered a pre-set stopping rule. Separately, 7.2% and 7.7% of participants in each group were recorded as having relapsed — meaning the virus became detectable again during the follow-up period after it had previously been undetectable. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 25653396) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Hepatitis C Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have a long-term (chronic) hepatitis C infection of a specific type called "genotype 1," with a measurable level of the virus in your blood
- You have never had any treatment for hepatitis C before
- You have had a liver biopsy in the last 2 years, or you are willing to have one done during the screening period before the trial begins
- If you have liver scarring (cirrhosis), a specific protein level in your blood (AFP) must be at or below a certain level — if it is higher, you will need an ultrasound scan to check there is no growth on the liver
- If you are a woman who could become pregnant, or a man who has not had a vasectomy and whose partner could become pregnant, you must agree to use 2 reliable forms of birth control — from the start of screening until 6 months after your last dose of medication (for women) or 7 months (for men)
Who may not be able to join:
- You have a type of hepatitis C other than genotype 1, or you have more than one subtype of the virus at the same time
- You have an existing mental health (psychiatric) condition
- You have a history of serious liver failure or have significant liver problems beyond hepatitis C
- You are also infected with HIV or hepatitis B
- You currently have cancer, or have been diagnosed with cancer in the past 5 years (except for a type of skin cancer called basal cell carcinoma that has already been treated)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Janssen Infectious Diseases BVBA Clinical Trial, Janssen Infectious Diseases BVBA
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
8 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Drugs (SVR12 Planned)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.